News
November 12, 2024
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 5, 2024
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
October 4, 2024
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
August 29, 2024
TScan Therapeutics to Participate in Upcoming Investor Conferences
August 12, 2024
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
June 14, 2024
TScan Therapeutics Announces Updates to its Board of Directors
May 30, 2024
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
May 29, 2024
TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies
May 13, 2024
TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 9, 2024